Member Info for Gheko

If simply obtaining a rig then we would have heard by now.

For me it is just what percentage of the company will be given in exchange for a JV with a major.

News any time………

Read a couple of interesting articles over the weekend. One urging Anglo America to speed up the project for potash development in North Yorks bought from Sirius, spending millions as urgency for potash supply.

Another article about companies spending millions to produce clean Hydrogen. Serious money being pumped in.

So Helium One has a world class asset of clean Helium just waiting to be firmed up. This against the backdrop of urgent global need for clean Helium. So joint venture feeling more certain and with it a huge price rise on confirmation. No wonder strength of buying continuing.

Interesting week ahead……all aboard.

DM - we will give you 7.5% of the company in return for a rig and funding assistance with first couple of drills.

Major co - we want 40% of the company in return for J/V, funding multiple drills with multiple rigs.

DM - more than we wanted to give away but DEAL!

News coming, let’s see how any deal is structured. Onwards and upwards

Wouldn’t want to be out overnight! ?? 7am RNS?

Here comes the surge…….

This is not just a covid stock now but think of the amazing science they have here and the numerous applications for a saliva test for all sorts of diagnostics.

£15 million market cap is cheap as chips. Once DHSC pay up then circa 75% of that market cap will be in cash!!

Another £2k for me topped up and tomorrow it is showtime in getting in new ISA allowance. Onwards and upwards.

Look at the interview again and again. DM trying not to confirm we are looking at a joint venture talking about not wanting to let go too much at the front end,

Sense a deal with a major and multiple drilling coming up.. HUGE story coming here.

Solarius growing and growing. Next steps will be contracts to sell into fast food/ ready meal market plus everyday salt pots is my guess then IPO.

All these great companies are dwarfing our tiny market cap of circa £40 million. Many an aim company with multiples of that market cap and own nothing except a licence to try and find gold/oil etc! Onwards and upwards. The profit takers will regret not enjoying the 2022 monetisation. Roll on £1

Not for me Sir. On record that £1 is a very decent bet. Firming up and there is some strong buying behind it.

Building up to results where NAV going way north. Sum of the parts worth a £1 easy plus who knows, maybe someone seeing the value and ready to make an offer?

Either way a top investment.

BELL on the move north again. Value of TEK just keeps rising!

50,000 blocks going through. Is our new 5% shareholder increasing? Don’t blame him…cheap as chips used to be!

Short term chart for Bell puts it north of £1.50 in a few weeks. That’s circa £26 million value to TEK!

Wakey wakey investors. Some folk buy complete dog with fleas stocks with no fundamentals, assets etc yet have overlooked the golden ticket of TEK which will monetise its investments this year and which are getting more valuable all the time.

Know where my ever topping up holding is! Onwards and upwards

Wakey wakey market…….BELL going £2 plus easily so TEK going to follow.

Lucyd IPO news anytime. Market starting to move. All aboard.

RNS for BELL. The scale up now is truly global for them and with their shares already up 16% it means TEK is now even more fundamentally undervalued.

Having some more myself this morning. One of best investment opportunities out there.

Folk seem to have missed the hidden gems but great for those who want to make serious money.

The world has changed with the pandemic. Flow testing has accelerated by years and will be in multiple industries. Announced today water testing plus health testing etc. can’t see a doctor but here get yourself a test!

Going forward there will be multiple collaborations, consolidation and mergers/takeovers in the industry.

Here we raised at 25p recently including big chunks of money from the management. DHSC owe us a significant amount of money whilst market cap is tiny.

A hidden gem for those willing to see the future.

Abingdon Health plc

("Abingdon" or "the Company")



Strategic collaboration with DeepVerge plc

Focused on the development, manufacturing and commercialisation of lateral flow tests to support DeepVerge's Modern Water and Life Science divisions



York, U.K. 29 March 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, announces that it has signed a Memorandum of Understanding ("MoU") with DeepVerge plc (AIM: DVRG) ("DeepVerge"), an environmental and life science group that develops and applies AI and IoT technology for the analysis and identification of bacteria, virus and toxins, leading to a commercial agreement for development and manufacture of a range of lateral flow tests ("LFTs") for DeepVerge's Modern Water and Life Science divisions.



The MoU has been signed to enable the potential integration of the respective technologies of both DeepVerge and Abingdon. DeepVerge and Abingdon intend to enter into a longer-term commercial agreement, with Abingdon manufacturing and DeepVerge commercialising the new products through its production, sales, marketing and distribution channel partners around the world.



Modern Water

Modern Water is the environmental division of DeepVerge that has developed and commercialised cutting-edge technology focused on monitoring of contaminated water and decontamination of wastewater. Abingdon and DeepVerge will work on the development of LFT devices to detect dangerous pathogens and chemicals in household drinking and wastewater. This will add an extra layer of detection to the current Modern Water range of equipment and services by incorporating an LFT into a hand-held mobile unit. The results of these LFT devices can be digitally scanned using a mobile app, with the potential to incorporate Abingdon's proprietary AppDx® technology.



Future potential developments for water testing that are complementary to the current Modern Water portfolio include the pepper mottle mosaic virus as a potential marker for human faecal matter in water and the automated multiplexing project bringing in influenza A, influenza B, Cryptosporidium etc. into the testing format on a hand-held device.



Life Science

Abingdon and DeepVerge will also collaborate on the development of new lateral flow tests to be added to DeepVerge's life science home test portfolio, including hormone analysis related to menopause and associated skin changes, stress levels (cortisol), vitamin D, and other health markers related to conditions including diabetes, heart and liver function.



Gerard Brandon, CEO of DeepVerge plc, commented:

"DeepVerge's business model is built on collaborating and cooperating with partners such as Abingdon Health who have technologies and large production capacity to deliver solutions to major societal problems such as water contamination and the identification of human biomarkers for a range of

Two MOU’s announced in different sectors! All aboard…….

Abingdon Health PLC

29 March 2022

Abingdon Health plc

("Abingdon" or "the Company")

Strategic collaboration with Vatic Health Limited

Focused on the development, manufacturing and commercialisation of infectious disease lateral flow self-tests

York, U.K. 29 March 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, announces that it has signed a Memorandum of Understanding ("MoU") with leading diagnostic technology innovator Vatic Health Limited ("Vatic"), leading to a commercial agreement for the development and manufacture of a range of lateral flow tests ("LFTs") in the area of infectious disease.

Initially Abingdon and Vatic will focus on the development of an innovative influenza LFT, utilising Vatic's proprietary technology platform which identifies proteins via their surface biological mechanisms. The technology has been proven in the development of Vatic's KnowNow test (Spike Test in USA), an easy-to-use saliva COVID-19 test which is the only test that identifies the virus by mimicking the surface of a human cell. This means the test only identifies "infectious" or "active" copies of the virus which are capable of cell entry and thereby infecting a human cell. Other tests, such as PCR and lateral flow antigen tests, can pick up harmless viral fragments with the potential for users to test positive once they are no longer infectious. Furthermore, the unique detection mechanism of the KnowNow Test has been purposefully designed to be more robust to mutation than traditional antigen tests, making it "future-proofed" for ongoing COVID-19 testing. This technology will be applied to the development of an influenza LFT and could have the same potential benefits in terms of accuracy and sensitivity in picking up only those that are infectious, differentiating it from other commercially available tests.

Following signing of the MoU, Abingdon and Vatic intend to enter into a longer-term commercial agreement, with both parties developing infectious disease LFTs, Abingdon exclusively manufacturing these LFTs and both parties collaborating on the commercialisation of these innovative new products.

According to Global Market Insights(1) the infectious disease lateral flow testing market accounted for revenue of USD 2.4 billion in 2021 and is expected to show significant market growth from 2022 to 2028 owing to the rise in the prevalence and increased disease burden of infectious diseases.

Alex Sheppard, CEO of Vatic Health Limited, commented:

"We are excited to be deepening our collaboration with Abingdon Health and we look forward to extending the use of our proprietary technology from COVID-19 into other areas of unmet need to further address inequalities of access to health information through self-tests.

"This partnership is an important step on our journey to helping more pe

Some tasty buying going on. Not surprised. RNS very clear that we have options on drill rig just securing the right one for the job.

Anytime now the announcement of rig secured and then who, where etc will be announced.

CEO hone because those sorting the financials made it a condition of the restructuring/investment.

Just a thought …….

1. CEO had to go but will do nicely when the price eventually rises
2. Morrisons/bankers will back the business
3. Insist on slashing the remaining non profitable stores immediately.
4. Shareholders will take a hit via warrants being issued or dilutive share issue
5. Company survives and have a good story to tell and share price rises accordingly.
6. See point 1 - CEO does nicely!

No wonder the RNS shows this chap taking a significant stake. Excellent Vox analysis just shows what we have here and easy 50% short term upside.

Lots of news catalysts too to exceed that. Took another £6k worth today. All aboard the true value coming to your wallet/purse soon!